Table 2.
Demographic details of CHD patients with or without Qi deficiency syndrome.
| Qi deficiency (n = 21) | Non-Qi deficiency (n = 24) | P value | |
|---|---|---|---|
| Age | 59.76 ± 8.61 | 58.79 ± 7.32 | 0.685 |
| Gender (male/female) | 14/7 | 19/5 | 0.344 |
| BMI | 25.57 ± 2.49 | 26.77 ± 6.17 | 0.750 |
| Years of CHD | 3.71 ± 4.16 | 3.00 ± 3.24 | 0.419 |
| Diabetes combination | 13 (61.9%) | 17 (70.8%) | 0.526 |
| Hyperlipemia combination | 6 (28.6%) | 4 (16.7%) | 0.338 |
| Use of antiplatelet drugs | 21 (100%) | 24 (100%) | / |
| Use of nitrate esters drugs | 11 (52.4%) | 13 (54.2%) | 0.905 |
| Use of statins | 14 (66.7%) | 19 (79.2%) | 0.344 |
| Use of ACEI/ARB | 2 (9.5%) | 2 (8.3%) | 0.889 |
| Use of beta blocker | 12 (57.1%) | 16 (66.7%) | 0.511 |
| Use of calcium channel antagonist | 21 (100%) | 24 (100%) | / |